Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://journals.lww.com/immunotherapy-journal/abstract/2001/03000/mannan_mucin_1_peptide_immunization__influence_of.12.aspx, but it redirected us to https://journals.lww.com/immunotherapy-journal/abstract/2001/03000/mannan_mucin_1_peptide_immunization__influence_of.12.aspx. The analysis below is for the second page.

Title[redir]:
Journal of Immunotherapy
Description:
es. On this basis, three phase I trials were performed in patients with adenocarcinoma to evaluate the tnxicity and the immunologic responses to mannan MUC1. Forty-one patients with metastatic or locally advanced carcinoma of the breast (trial 1), colon (trial 2), and various adenocarcinomas (trial 3) received increasing doses of M-FP (1 to 300 ΞΌg). The immunizations were given at weekly intervals (weeks 1 to 3) and repeated in weeks 7 to 9. Cyclophosphamide (to increase cellular immunity) was given on weeks 1 and 4. M-FP was given intramuscularly in trial 1 and intraperitoneally in trial 2. No toxic effects occurred, and delayed-type hypersensitivity responses were present only as a microscopic lymphocytic infiltration. Overall, approximately 60% of the patients had high-titer MUC1 immunoglobulin G1 antibody responses, with the intraperitoneal route yielding approximately 10-fold higher responses. Cellular responses (proliferation, cytotoxic T cells, or CD8 T cells secreting tumor necrosis factor-Ξ± Ξ±nd interferon-Ξ³ in response to MUC1 stimulation in vitro) were found in 28% of the patients, which was similar to that seen without cyclophosphamide. In most patients, disease progressed, but in five it remained stable. In addition, there were no objective responses. M-FP is not toxic and induces immune responses that were amplified by the intraperitoneal route of immunization. Cyclophosphamide was of no benefit....

Matching Content Categories {πŸ“š}

  • Health & Fitness
  • News & Politics
  • Telecommunications

Content Management System {πŸ“}

What CMS is doi.org built with?


Doi.org uses MYBB.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of doi.org audience?

🌍 Impressive Traffic: 500k - 1M visitors per month


Based on our best estimate, this website will receive around 600,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {πŸ’Έ}

We can't see how the site brings in money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Doi.org might be cashing in, but we can't detect the method they're using.

Keywords {πŸ”}

journal, responses, muc, patients, trial, issue, cyclophosphamide, mfp, access, subscribe, alerts, authors, abstract, mannan, route, weeks, log, register, logo, articles, advanced, issues, mucin, immunization, immunotherapy, buy, breast, induces, cytotoxic, cellular, toxic, approximately, intraperitoneal, cells, text, subscribers, request, browse, content, submit, service, privacy, policy, secondary, search, rosenberg, interview, info, previous, clinical,

Topics {βœ’οΈ}

delayed-type hypersensitivity responses locally advanced carcinoma anti-tumor responses full text access journal authors submit received increasing doses microscopic lymphocytic infiltration artificial intelligence training induces immune responses increase cellular immunity etoc alerts mucin muc1 toxic effects occurred intraperitoneal route mannan muc1 buy abstract service request 800-638-3030 register subscribe individual subscribers log journal tables high frequency oxidized mannan cellular responses m-fp issue immunologic responses objective responses muc1 conjugated muc1 stimulation cells website subscribe journal center submit injection karanikas chin-swee greatly increased potential target mannose receptor weekly intervals approximately 60% disease progressed remained stable immunization email inbox rights reserved data mining breast cancer route content authors

Questions {❓}

  • Not a Subscriber?

Social Networks {πŸ‘}(1)

External Links {πŸ”—}(57)

Analytics and Tracking {πŸ“Š}

  • Comscore
  • Google Analytics
  • Google Tag Manager

Libraries {πŸ“š}

  • Bootstrap
  • FontAwesome
  • jQuery
  • Zoom.js

Emails and Hosting {βœ‰οΈ}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {πŸ“¦}

  • Cookielaw
  • Jsdelivr
  • Scite
  • Wolterskluwer

4.83s.